BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19152223)

  • 1. Chemical and molecular basis of the carcinogenicity of Aristolochia plants.
    Schmeiser HH; Stiborovà M; Arlt VM
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):141-8. PubMed ID: 19152223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
    Stiborova M; Frei E; Arlt VM; Schmeiser HH
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
    Arlt VM; Stiborova M; Schmeiser HH
    Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats.
    Bárta F; Dedíková A; Bebová M; Dušková Š; Mráz J; Schmeiser HH; Arlt VM; Hodek P; Stiborová M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer.
    Stiborová M; Arlt VM; Schmeiser HH
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.
    Schmeiser HH; Nortier JL; Singh R; Gamboa da Costa G; Sennesael J; Cassuto-Viguier E; Ambrosetti D; Rorive S; Pozdzik A; Phillips DH; Stiborova M; Arlt VM
    Int J Cancer; 2014 Jul; 135(2):502-7. PubMed ID: 24921086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy.
    Stiborová M; Frei E; Arlt VM; Schmeiser HH
    Mutat Res; 2008; 658(1-2):55-67. PubMed ID: 17851120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
    Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
    Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
    Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
    Hollstein M; Moriya M; Grollman AP; Olivier M
    Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.
    Arlt VM; Stiborová M; vom Brocke J; Simões ML; Lord GM; Nortier JL; Hollstein M; Phillips DH; Schmeiser HH
    Carcinogenesis; 2007 Nov; 28(11):2253-61. PubMed ID: 17434925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.
    Schmeiser HH; Kucab JE; Arlt VM; Phillips DH; Hollstein M; Gluhovschi G; Gluhovschi C; Modilca M; Daminescu L; Petrica L; Velciov S
    Environ Mol Mutagen; 2012 Oct; 53(8):636-41. PubMed ID: 22987305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.
    Bellamri M; Brandt K; Brown CV; Wu MT; Turesky RJ
    Arch Toxicol; 2021 Jun; 95(6):2189-2199. PubMed ID: 33938965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer.
    Stiborová M; Martínek V; Frei E; Arlt VM; Schmeiser HH
    Curr Drug Metab; 2013 Jul; 14(6):695-705. PubMed ID: 23701164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
    Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
    Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats.
    Stiborová M; Bárta F; Levová K; Hodek P; Frei E; Arlt VM; Schmeiser HH
    Arch Toxicol; 2015 Nov; 89(11):2141-58. PubMed ID: 25209566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR.
    Arlt VM; Schmeiser HH; Pfeifer GP
    Carcinogenesis; 2001 Jan; 22(1):133-40. PubMed ID: 11159751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.
    Yun BH; Rosenquist TA; Sidorenko V; Iden CR; Chen CH; Pu YS; Bonala R; Johnson F; Dickman KG; Grollman AP; Turesky RJ
    Chem Res Toxicol; 2012 May; 25(5):1119-31. PubMed ID: 22515372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.
    Stiborová M; Frei E; Breuer A; Bieler CA; Schmeiser HH
    Exp Toxicol Pathol; 1999 Jul; 51(4-5):421-7. PubMed ID: 10445409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH : cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy.
    Stiborová M; Hájek M; Frei E; Schmeiser HH
    Gen Physiol Biophys; 2001 Dec; 20(4):375-92. PubMed ID: 11989648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.